NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration

2025-01-10 04:37:23 ET

Summary

• NervGen completed enrollment for its phase 2 trial in spinal cord injury, setting the countdown for topline results in Q2, 2024.
• The research suggests that the company may have a solution for nervous system regeneration, which has been considered impossible for over a century.
• NervGen's stock will appear significantly undervalued if the upcoming phase 2 SCI results are positive.

NervGen ([[NGENF]], [[NGEN:CA]], CVE:NGEN) announced completion of enrollment of patients in its proof-of-concept phase 1b/2a clinical trial for spinal cord injury ((SCI)) at the turn of the new year (2025). Thus, the countdown for the completion of the 16-week trial begins, and the company expects topline data in the second quarter of 2025. NervGen will soon have a distinct chance to demonstrate what has been considered impossible for a century — the regeneration of nervous connections through scar — potentially enabling victims of paralysis to walk again.

his Nobel Prize worthy effort has a considerable amount of scientific backing with several SCI studies along with accompanying studies in other neurological degenerative diseases, such as stroke and multiple sclerosis ((MS)) showing preclinical efficacy.

This scenario seems almost too good to be true for investors. Could a small Canadian biotech company — with a market capitalization less than $200 million USD — potentially upend the long-held scientific belief that recovery from serious nerve injury is virtually impossible?...

Read the full article on Seeking Alpha

For further details see: